Compare BVS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | ESPR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 731.9M |
| IPO Year | 2016 | 2013 |
| Metric | BVS | ESPR |
|---|---|---|
| Price | $10.68 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.00 | $8.75 |
| AVG Volume (30 Days) | 403.4K | ★ 14.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 60.71 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $403,135,000.00 |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | $12.81 |
| P/E Ratio | $30.65 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $5.81 | $0.73 |
| 52 Week High | $10.76 | $4.18 |
| Indicator | BVS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 71.67 |
| Support Level | $8.43 | $2.37 |
| Resistance Level | $10.76 | $3.33 |
| Average True Range (ATR) | 0.43 | 0.11 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 94.26 | 98.13 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.